Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Ilava – page 8

209 clinical trials in Ilava, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Ilava at a glance
209
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

209 trials in Ilava

Open in trial search

Psoriatic arthropathy

Not recruiting

Study of sonelokimab and risankizumab in adults with psoriatic arthritis who did not respond well to previous TNF inhibitor treatment

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:MoonLake Immunotherapeutics AG

Skin ulcer

Not recruiting

Study on the Effectiveness of Allo-APZ2-CVU for Patients with Long-Term, Non-Healing Venous Leg Ulcers

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:ALLO-APZ2-EB
  • Sponsor:Rheacell GmbH & Co. KG

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Migraine

Not recruiting

Study on Lu AG09222 for Preventing Migraines in Adults Unresponsive to Previous Treatments

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years
  • Substances:Lu Ag09222
  • Sponsor:H. Lundbeck A/S

Psoriatic arthropathy

Not recruiting

Study on the Effects and Safety of Guselkumab for Patients with Active Psoriatic Arthritis

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Hypertriglyceridaemia

Not recruiting

Study of Plozasiran for Adults with Severe Hypertriglyceridemia

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Hot flush

Not recruiting

Study of Fezolinetant for Hot Flashes in Women with Hormone Receptor-Positive Breast Cancer Receiving Hormone Therapy

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Fezolinetant
  • Sponsor:Astellas Pharma Global Development Inc.

Hypertriglyceridaemia

Not recruiting

Study to Evaluate Plozasiran for Adults with High Triglycerides

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Rheumatoid arthritis

Not recruiting

Study on the Effects of AP1189 and Methotrexate for Patients with Early Rheumatoid Arthritis and Active Inflammation

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Synact Pharma ApS

Study on the Effects of Semaglutide on Diabetic Eye Disease in People with Type 2 Diabetes

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Psoriatic arthropathy

Not recruiting

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis and Inadequate Response to DMARD Therapy

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Ilava

What the registry says about research in the country

01 Cardiovascular Diseases

The clinical trial activity in Ilava includes research in cardiovascular diseases, with a focus on improving protection against major heart-related events and related complications. These studies are exploring new ways to reduce risk in people living with established or high-risk heart conditions.

  • Atherosclerotic cardiovascular disease
  • Established cardiovascular disease
  • High cardiovascular risk
  • Hypertension

The goal is to evaluate whether new treatments can better prevent serious outcomes such as heart attack, stroke, heart failure, and cardiovascular death.

02 Nutritional and Metabolic Diseases

Another key area in this research landscape is nutritional and metabolic diseases, especially conditions linked to excess weight and metabolic risk. The trials are looking at therapies that may support weight reduction while also improving broader health outcomes.

  • Obesity
  • Overweight
  • Chronic kidney disease

In Ilava, this work is aimed at understanding whether newer treatments can help lower the burden of obesity-related complications and support kidney health at the same time.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.